Evaluation of KCB-328, a new IKr blocking antiarrhythmic agent in pacing induced canine atrial fibrillation

Europace

Volumn 6, Issue 5, 2004, Pages 384-391

  Chandra, Parag ^a   Rosen, Tove S ^a   Yeom, Zi Ho ^b   Lee, Kiho ^b   Kim, Hak Yeop ^b   Danilo Jr , Peter ^a   Rosen, Michael R ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b C and C Research Laboratories   (South Korea)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Chronic heart block; Effective refractory period; Potassium channel blockade; Proarrhythmia

Indexed keywords

ANTIARRHYTHMIC AGENT; DOFETILIDE; N [3 AMINO 4 [2 [N (3,4 DIMETHOXYPHENETHYL) N METHYLAMINO]ETHOXY]PHENYL]METHANESULFONAMIDE; NEW DRUG; POTASSIUM CHANNEL BLOCKING AGENT; PROPAFENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLETE HEART BLOCK; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; EVALUATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART ELECTROPHYSIOLOGY; HEART LEFT ATRIUM; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART PROARRHYTHMIA; HEART RIGHT ATRIUM; HEART VENTRICLE; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZATION;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART ATRIA; HEART VENTRICLES; PHENETHYLAMINES; POTASSIUM CHANNEL BLOCKERS; PROPAFENONE; RANDOM ALLOCATION; SODIUM CHANNEL BLOCKERS; SULFONAMIDES;

EID: 4344577428     PISSN: 10995129     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eupc.2004.05.006     Document Type: Article

References (19)

1. Furberg C.D. Psaty B.M. Manolio T.A. Gardin J.M. Smith V.E. Rautaharja P.M. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study) Am J Cardiol 74 1994 236-241
2. Allessie M.A. Boyden P.A. Camm A.J. et al. Pathophysiology and prevention of atrial fibrillation Circulation 103 2001 769-777
3. + current by dofetilide Circ Res 72 1993 75-83
4. Krafte D.S. Volberg W.A. Voltage dependence of cardiac delayed rectifier block by methanesulfonamide class III antiarrhythmic agents J Cardiovasc Pharmacol 23 1994 37-41
5. Kr) in AT-1 cells. Concentration-, time-, voltage- and use dependent effects Circulation 91 1995 1799-1806
6. Lee K. Lee J.Y. Kim H.Y. Kwon L.S. Shin H.S. Tanabe S. et al. KCB-328: a novel class III antiarrhythmic agent with little reverse frequency dependence in isolated guinea pig myocardium J Cardiovasc Pharmacol 31 1998 609-617
7. Pedersen O.D. Bagger H. Keller N. Marchant B. Kober L. Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigation of arrhythmia and mortality on dofetilide (DIAMOND) substudy Circulation 104 2001 292-296
8. Singh S. Zoble R.G. Yellen L. Brodsky M.A. Feld G.K. Berk M. et al. For the Dofetilide Atrial Fibrillation Investigators Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter. The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study Circulation 102 2000 2385-2390
9. Steiner C. Kovalik A.T. A simple technique for production of chronic complete heart block in dog J Appl Physiol 25 1968 631-632
10. Rosen M.R. Plotnikov A.N. The pharmacology of cardiac memory Pharmacol Ther 94 2002 63-75
11. Crijns H.J. Van den Berg M.P. Van Gelder I.C. Van Veldhuisen D.J. Management of atrial fibrillation in the setting of heart failure Eur Heart J 18 1997 C45-C49
12. Pedersen O.D. Bagger H. Kober L. Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction Circulation 100 1999 376-380
13. Rahme M.M. Ungab G.A. Wadhwa M. Al-Kandari F. Yao B. Gupta A. Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter J Cardiovasc Pharmacol Ther 6 2001 297-306
14. Xue Y. Tanabe S. Nabuchi Y. Hashimoto K. Antiarrhythmic effects of a novel class III drug, KCB-328 on canine ventricular arrhythmia modes J Cardiovasc Pharmacol 32 1998 239-247
15. + channels J Pharmacol Exp Ther 302 2002 314-319
16. + current in cardiac myocytes by dofetilide J Pharmacol Exp Ther 262 1992 809-817
17. Snyders D.J. Chaudhary A. High affinity open channel block by dofetilide of HERG expresses in a human cell line Mol Pharmacol 49 1996 949-955
18. Lee K. Park J.B. Jeon B.H. Kim K.-J. Ryu P.D. Kwon L.-S. et al. Differential recovery of action potential duration and HERG currents from the effects of two methanesulfonamide class III antiarrhythmic agents, KCB-328 and dofetilide J Cardiovasc Pharmacol 42 5 2003 648-655
19. Wang J. Bourne G.W. Wang Z. Villemaire C. Talajic M. Nattel S. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation Circulation 88 1993 1030-1044